{"disease":{"id":"moderately-to-severely-active-crohns-disease","name":"moderately to severely active crohns disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06819878","title":"A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06819891","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":425,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07298421","title":"A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}